Tags : Pain

MSD Signs a License Agreement with King’s College London &

Shots: King’s and Wellcome to receive $340M as development and commercial milestone and royalties on sales. MSD to get a license for conducting lead optimization, preclinical & clinical research The focus of an agreement is to develop therapies for chronic pain and to meet unmet medical needs of patients Professor McNaughton at King’s identifies target […]Read More

Imbrium Signs a License Agreement with TetraGenetics for its TetraExpress

Shots: TetraGenetics to receive $25M upfront, $248M milestones as contingent payments, FTE payments and royalties upto 7% on sales of product. Imbrium to get license for TetraGenetics’ TetraExpress Technology with an option to develop therapies post IND submission for pain and autoimmune disorders The focus of the agreement is to develop non-opioid therapies with advancement […]Read More

Pfizer and Eli Lilly Report Results of Tanezumab in P-III

Shots: The P-III OA study involves assessing of tanezumab (2.5mg/5mg, SC) vs PBO in 849 patients in the ratio (1:1:1) with moderate-to-severe OA pain of the knee or hip across EU and Japan for 24 wks. The study showed a meeting in all 1EPs improvement in pain, physical function with well-tolerated results and has shown […]Read More

Lilly Acquires Hydra Biosciences with its Pre-Clinical Pain Program for

Shots: Lilly to acquire Hydra, in all stock transaction with its all pre-clinical pain program of TRPA1 antagonists The focus of the acquisition is to develop treatments for chronic pain and understand TRP pathway in pain signaling, further initiate clinical trials Hydra’s Transient Receptor Potential (TRP) channel program consists of group of non-selective cation channels indicated for the treatment […]Read More